JP7198547B1 - Prophylactic or therapeutic agents, antibacterial agents, and oral compositions - Google Patents

Prophylactic or therapeutic agents, antibacterial agents, and oral compositions Download PDF

Info

Publication number
JP7198547B1
JP7198547B1 JP2022144746A JP2022144746A JP7198547B1 JP 7198547 B1 JP7198547 B1 JP 7198547B1 JP 2022144746 A JP2022144746 A JP 2022144746A JP 2022144746 A JP2022144746 A JP 2022144746A JP 7198547 B1 JP7198547 B1 JP 7198547B1
Authority
JP
Japan
Prior art keywords
agents
honey
oral
gingivalis
honeydew
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022144746A
Other languages
Japanese (ja)
Other versions
JP2024039967A (en
Inventor
大城日出男
中島宏
向井克之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUTE OF ORIENTAL MEDICAL SCIENCE CO., LTD.
Original Assignee
INSTITUTE OF ORIENTAL MEDICAL SCIENCE CO., LTD.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUTE OF ORIENTAL MEDICAL SCIENCE CO., LTD. filed Critical INSTITUTE OF ORIENTAL MEDICAL SCIENCE CO., LTD.
Priority to JP2022144746A priority Critical patent/JP7198547B1/en
Application granted granted Critical
Publication of JP7198547B1 publication Critical patent/JP7198547B1/en
Priority to PCT/JP2023/031000 priority patent/WO2024057898A1/en
Publication of JP2024039967A publication Critical patent/JP2024039967A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • A61K35/64Insects, e.g. bees, wasps or fleas
    • A61K35/644Beeswax; Propolis; Royal jelly; Honey
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • A61K36/15Pinaceae (Pine family), e.g. pine or cedar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9755Gymnosperms [Coniferophyta]
    • A61K8/9767Pinaceae [Pine family], e.g. pine or cedar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A61Q11/02Preparations for deodorising, bleaching or disinfecting dentures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Insects & Arthropods (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Animal Husbandry (AREA)
  • Vascular Medicine (AREA)
  • Medical Informatics (AREA)

Abstract

【課題】安全性が高く、低濃度で各種疾患の原因となるジンジバリス菌等の口腔細菌の増殖を抑制する抗菌剤を提供する。【解決手段】甘露ハチミツを有効成分とするとすることで、ジンジバリス菌等の口腔細菌の増殖を効率的に抑制し、口腔細菌を原因とする歯周病、虫歯、口臭、認知症、糖尿病、動脈硬化症などの疾患を予防又は治療する組成物を見出した。【選択図】なし[PROBLEMS] To provide an antibacterial agent that is highly safe and inhibits the growth of oral bacteria such as gingivalis that cause various diseases at low concentrations. [Solution] By using honeydew honey as an active ingredient, it is possible to effectively suppress the growth of oral bacteria such as gingivalis gingivalis. Compositions have been found to prevent or treat diseases such as sclerosis. [Selection figure] None

Description

本発明は、口腔細菌を原因とする疾患の予防又は治療剤、及び抗菌剤、並びに、予防若しくは治療剤又は抗菌剤を含有する口腔用組成物に関する。 TECHNICAL FIELD The present invention relates to a preventive or therapeutic agent for diseases caused by oral bacteria, an antibacterial agent, and an oral composition containing the preventive or therapeutic agent or antibacterial agent.

歯周病は、歯肉炎又は歯槽膿漏等、歯周組織に炎症を引き起こす症状をともなう疾患である。歯周病の原因菌である口腔細菌としては、プレボテラ・インターメディア(Prevotella intermedia)、タンネレラ・フォーサイセンシス(Tannerella forsythensis)、トレポネマ・デンティコラ(Treponema denticola)等が知られているが、慢性歯周病のレッド・コンプレックス(最重要歯周病原細菌)はプロフィロモナス・ジンジバリス(Porphyromonas gingivalis. 以下、「ジンジバリス菌」と記す。)である。歯周病の予防にはプラークコントロールが有用である。歯周病の中には、プラークを原因としないものがあり、重症化した場合には、抗生物質による化学的療法等を受けなくてはならない。患者に投与される薬剤には、副作用として種々の消化器系疾患を誘発する懸念があり、安全な原因菌の除去剤が望まれていた。また、最近では、ジンジバリス菌は、歯周病以外の疾患との関連も多く報告されている。例えば、ジンジバリス菌成分が、アルツハイマー病患者の脳内で検出されたことから、アルツハイマー病を引き起こす一連の事象に関与している可能性が指摘されている(非特許文献1)。また、ジンジバリス菌等の歯周病原因菌が心血管疾患発症の要因である可能性があること(非特許文献2)、及び、ジンジバリス菌が脳梗塞や狭心症、心筋梗塞などを引き起こすアテローム性動脈硬化症という炎症反応を悪化させる可能性があること(非特許文献3)も指摘されている。さらには、歯周病菌の存在と糖尿病発症との強い相関があること(非特許文献4)も報告されている。 Periodontal disease is a disease accompanied by symptoms such as gingivitis or alveolar pyorrhea that cause inflammation in periodontal tissue. Prevotella intermedia, Tannerella forsythensis, Treponema denticola, etc. are known as oral bacteria that cause periodontal disease. The red complex of disease (the most important periodontal pathogenic bacterium) is Porphyromonas gingivalis (hereinafter referred to as "gingivalis"). Plaque control is useful for prevention of periodontal disease. Some periodontal diseases are not caused by plaque, and when they become severe, they must undergo chemotherapy using antibiotics or the like. There is a concern that drugs administered to patients may induce various digestive system diseases as side effects, and safe agents for removing causative bacteria have been desired. Recently, many reports have also been made that B. gingivalis is associated with diseases other than periodontal disease. For example, gingivalis components have been detected in the brains of Alzheimer's disease patients, suggesting that they may be involved in a series of events leading to Alzheimer's disease (Non-Patent Document 1). In addition, periodontal disease-causing bacteria such as Lactobacillus gingivalis may be a factor in the onset of cardiovascular disease (Non-Patent Document 2), and Lactobacillus gingivalis causes cerebral infarction, angina pectoris, myocardial infarction, etc. It has also been pointed out that it may exacerbate the inflammatory reaction known as arteriosclerosis (Non-Patent Document 3). Furthermore, it has also been reported that there is a strong correlation between the presence of periodontal bacteria and the onset of diabetes (Non-Patent Document 4).

ジンジバリス菌と様々な疾患との関連が指摘される中で、ジンジバリス菌に作用して、上記のような疾患を予防又は治療することのできる予防又は治療剤への需要が高まっている。これに対し、例えば、特許文献1には、ストレプトコッカス・フェカリス(Streptococcus faecalis)菌を含有した口腔用組成物が歯周病関連細菌のジンジバリス菌類に対して選択的な作用を示し、口腔内フローラを良い環境に導くことが提示されている。 As the relationship between Lactobacillus gingivalis and various diseases has been pointed out, there is an increasing demand for preventive or therapeutic agents that act on Lactobacillus gingivalis to prevent or treat the above diseases. On the other hand, for example, in Patent Document 1, an oral composition containing Streptococcus faecalis bacteria exhibits a selective action against periodontal disease-related bacteria, Gingivalis fungi, and improves oral flora. It is proposed to lead to a better environment.

ジンジバリス菌に作用して効果を発揮する成分をハチミツ類に限定すると、ヤハシハチミツ及び/又はローヤルゼリーがジンジバリス菌の除菌作用を示し、歯周疾患の予防又は改善剤となることが報告されている(特許文献2)。また、マヌカハニーはジンジバリス菌に対する抗菌作用が、一般的な花ハチミツよりも高いことも報告されている(非特許文献5)。 It has been reported that when the components that act on and exert effects on Lactobacillus gingivalis are limited to honeys, Yahashi honey and/or royal jelly exhibit a sterilizing effect on Lactobacillus gingivalis and serve as a preventive or ameliorating agent for periodontal disease ( Patent document 2). It has also been reported that manuka honey has a higher antibacterial activity against gingivalis than common flower honey (Non-Patent Document 5).

特許第6351985号公報Japanese Patent No. 6351985 特許第6047105号公報Japanese Patent No. 6047105

石田直之ら,歯周病はアルツハイマー病を悪化させる,日歯周誌 2018; 60: 147-152Naoyuki Ishida et al., Periodontal disease aggravates Alzheimer's disease, Journal of the Periodontal Society of Japan 2018; 60: 147-152 Gaetti-Jardim, E. Jr, et al., Quantitativedetection of periodontopathic bacteria in atherosclerotic plaques from coronaryarteries., Journal of Medical Microbiology, 2009; 58: 1568-1575.Gaetti-Jardim, E. Jr, et al., Quantitativedetection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries., Journal of Medical Microbiology, 2009; 58: 1568-1575. Dorn, B. R., et al., Porphyromonas gingivalis Traffics toAutophagosomes in Human Coronary Artery Endothelial Cells., Infection and Immunity, 2001; 69: 5698-5708.Dorn, B. R., et al., Porphyromonas gingivalis Traffics to Autophagosomes in Human Coronary Artery Endothelial Cells., Infection and Immunity, 2001; 69: 5698-5708. Demmer RT, Jacobs DR,Desvarieux M., Periodontal disease and incident type 2 diabetes., Diabete Care, 2008; 31: 1373-1379Demmer RT, Jacobs DR, Desvarieux M., Periodontal disease and incident type 2 diabetes., Diabete Care, 2008; 31: 1373-1379 Sigrun Eick et al., Honey - a potential agent against Porphyromonas gingivalis: an in vitro study, BMC Oral Health, 2014; 14: 24Sigrun Eick et al., Honey - a potential agent against Porphyromonas gingivalis: an in vitro study, BMC Oral Health, 2014; 14: 24

本発明は、口腔細菌を原因とする疾患に対する新規の予防又は治療剤、及び口腔細菌に対する新規の抗菌剤を提供することを目的とする。 An object of the present invention is to provide a novel prophylactic or therapeutic agent for diseases caused by oral bacteria, and a novel antibacterial agent for oral bacteria.

本発明は、上記課題を解決するために鋭意研究を重ねた結果、甘露ハチミツを有効成分として用いることで、一般的な花ハチミツよりもジンジバリス菌に代表される口腔細菌の増殖を低濃度で抑制できることを見出し、本発明を完成するに至った。 As a result of intensive research to solve the above problems, the present invention uses honeydew honey as an active ingredient to suppress the growth of oral bacteria represented by Lactobacillus gingivalis at a lower concentration than common flower honey. I found that it can be done, and came to complete the present invention.

すなわち、本発明は、口腔細菌が原因で発症する疾病の予防又は治療剤であって、前記疾患が、歯周病、虫歯、口臭、認知症、糖尿病、動脈硬化症から選択される1種以上である、甘露ハチミツを有効成分とする疾病の予防又は治療剤である。さらに別の発明は、甘露ハチミツを有効成分とする、口腔細菌に対する抗菌剤である。口腔細菌は、ポルフィロモナス・ジンジバリスであり得る。 That is, the present invention provides a prophylactic or therapeutic agent for diseases caused by oral bacteria, wherein the disease is one or more selected from periodontal disease, tooth decay, halitosis, dementia, diabetes, and arteriosclerosis. is a preventive or therapeutic agent for diseases containing honeydew honey as an active ingredient. Yet another invention is an antibacterial agent against oral bacteria containing honeydew honey as an active ingredient. The oral bacterium can be Porphyromonas gingivalis.

また、本発明は、甘露ハチミツが、松の木由来である疾病の予防又は治療剤及び抗菌剤であり、疾病の予防又は治療剤及び抗菌剤を含む歯磨き剤、洗口剤、塗布剤、マウススプレー、貼付剤、シート剤、口腔内徐放剤、咀嚼剤、口腔内溶解剤、口腔内崩壊剤、義歯ケア剤、舌ケア剤、口中清涼剤、トローチ剤、含嗽剤、食品組成物、サプリメント、及びドリンク剤から選ばれる口腔用組成物である。 In addition, the present invention provides honeydew honey as a preventive or therapeutic agent and an antibacterial agent for diseases derived from pine trees, and toothpastes, mouthwashes, ointments, mouth sprays, and mouthwashes containing the preventive or therapeutic agents and antibacterial agents for diseases. Patches, sheets, oral sustained release agents, chewing agents, oral dissolving agents, orally disintegrating agents, denture care agents, tongue care agents, mouth fresheners, lozenges, mouthwashes, food compositions, supplements, and It is an oral composition selected from drinks.

甘露ハチミツは、すでに食品として全世界で食経験のある天然物質であり、ジンジバリス菌等の口腔細菌に対して低濃度で優れた抗菌作用を有している。したがって、本発明を用いた場合では、耐性菌出現のリスクが低く、ジンジバリス菌等の口腔細菌の増殖の抑制や、ジンジバリス菌等の口腔細菌に関連する疾患の予防または治療に非常に有用である。 Honeydew honey is a natural substance that has already been eaten as a food all over the world, and has an excellent antibacterial effect against oral bacteria such as Lactobacillus gingivalis at a low concentration. Therefore, when the present invention is used, the risk of emergence of resistant bacteria is low, and it is very useful for suppressing the growth of oral bacteria such as Lactobacillus gingivalis and for preventing or treating diseases related to oral bacteria such as Lactobacillus gingivalis. .

以下、本発明の好適な実施形態について詳細に説明する。ただし、本発明は以下の実施形態に限定されるものではない。 Preferred embodiments of the present invention are described in detail below. However, the present invention is not limited to the following embodiments.

本発明において、抗菌剤とは、歯周病の最重要歯周病原細菌であると言われているポルフィロモナス・ジンジバリス等の口腔細菌の増殖を抑制することができる組成物を意味する。本発明の抗菌剤は、ジンジバリス菌等の口腔細菌に関連する疾患の予防又は治療のために用いることができる。 In the present invention, an antibacterial agent means a composition capable of suppressing the growth of oral bacteria such as Porphyromonas gingivalis, which is said to be the most important periodontal pathogenic bacteria in periodontal disease. The antibacterial agent of the present invention can be used for prevention or treatment of diseases associated with oral bacteria such as Lactobacillus gingivalis.

本発明において有効成分として用いられる甘露ハチミツは、別名として「甘露蜜」、「ハニーデューハニー」と呼ばれ、ヨーロッパでは「森の蜜」とも呼ばれる樹木由来のハチミツである。甘露ハチミツは、樹液を食べるアブラムシやカイガラムシが分泌する糖分の高い甘露をミツバチが集めて作られたものである。利用される主な樹木は、松の木、オーク、菩提樹、アカシア、レザーウッド、トチ、樫の木、もみの木などであり、主にヨーロッパやアジアの一部で生産されている。国内では、小笠原諸島で生産されている「島ハチミツ」の多くが甘露ハチミツである。一般的には、ミネラルやポリフェノールが豊富な希少なハチミツとして知られている。 Honeydew honey used as an active ingredient in the present invention is also known as "honeydew honey" or "honeydew honey", and is a tree-derived honey also called "forest honey" in Europe. Honeydew honey is made by honeybees collecting the sugar-rich honeydew secreted by aphids and scale insects that feed on tree sap. The main trees used are pine, oak, linden, acacia, leatherwood, conker, oak and fir, mainly produced in Europe and parts of Asia. In Japan, most of the "island honey" produced in the Ogasawara Islands is honeydew honey. Generally, it is known as a rare honey rich in minerals and polyphenols.

本発明の疾患の予防又は治療剤及び抗菌剤は、甘露ハチミツを有効成分とする。ハチミツには、花の蜜をミツバチが集めて作る花ハチミツと、樹木由来の樹液を食べる昆虫が分泌する甘露をミツバチが集めて作る甘露ハチミツの、大きく分けて2種類が存在する。本発明では、甘露ハチミツであれば特に限定はされないが、松の木由来のパインハニーが好ましく、ギリシャ産もしくはトルコ産のパインハニーがさらに好ましい。 The prophylactic or therapeutic agent for diseases and the antibacterial agent of the present invention contain honeydew honey as an active ingredient. Honey is roughly divided into two types: flower honey made by honeybees collecting nectar from flowers, and honeydew honey made by honeybees collecting honeydew secreted by insects that eat sap derived from trees. In the present invention, honeydew honey is not particularly limited, but pine honey derived from pine trees is preferable, and Greek or Turkish pine honey is more preferable.

本発明の疾患の予防又は治療剤及び抗菌剤は、ハチミツを有効成分としているため、一般的な使用方法として任意の食品素材、例えば、牛乳、コーヒー、紅茶や果汁等の飲料、ヨーグルト等の乳製品、パンやサンドウィッチ等の食品、カレーなど各種料理に調味料として添加して用いることができる。 Since the preventive or therapeutic agent and the antibacterial agent for diseases of the present invention contain honey as an active ingredient, they are generally used with any food material, such as milk, coffee, beverages such as tea and fruit juice, and milk such as yogurt. It can be used as a seasoning added to products, foods such as bread and sandwiches, and various dishes such as curry.

また、本発明の疾患の予防又は治療剤及び抗菌剤は、歯磨き剤、洗口剤、塗布剤、マウススプレー、貼付剤、シート剤、口腔内徐放剤、咀嚼剤、口腔内溶解剤、口腔内崩壊剤、義歯ケア剤、舌ケア剤、口中清涼剤、トローチ剤、含嗽剤、食品組成物、サプリメント、及びドリンク剤から選ばれる口腔用組成物として用いることができる。 In addition, the preventive or therapeutic agent for diseases and the antibacterial agent of the present invention include toothpastes, mouthwashes, coating agents, mouth sprays, patches, sheets, oral sustained release agents, chewing agents, oral dissolving agents, oral cavity It can be used as an oral composition selected from disintegrants, denture care agents, tongue care agents, mouth fresheners, lozenges, gargles, food compositions, supplements, and drinks.

本発明の疾病の予防又は治療剤及び抗菌剤は、固体、液体、ペースト等のいずれの形態であっても良く、タブレット、カプセル剤、丸剤、散剤、細粒剤、顆粒剤、液剤等の形態であっても良い。これらの製剤は、薬理学的又は生理学的に許容される添加物(例えば、賦形剤、滑沢剤、結合剤、崩壊剤、安定剤、懸濁化剤、乳化剤、溶解補助剤等)を混合して製造することもできる。 The prophylactic or therapeutic agent for diseases and the antibacterial agent of the present invention may be in any form such as solid, liquid, paste, etc., and tablets, capsules, pills, powders, fine granules, granules, liquids, etc. It may be a form. These formulations contain pharmacologically or physiologically acceptable additives (e.g., excipients, lubricants, binders, disintegrants, stabilizers, suspending agents, emulsifiers, solubilizers, etc.) It can also be manufactured by mixing.

本発明の疾病の予防又は治療剤及び抗菌剤は、医薬品、医薬部外品、化粧品、食品、飼料又はそれらの成分などとして使用することができる。 The preventive or therapeutic agents and antibacterial agents for diseases of the present invention can be used as pharmaceuticals, quasi-drugs, cosmetics, foods, feeds, or components thereof.

さらに、本発明の疾患の予防又は治療剤及び抗菌剤においては、甘露ハチミツが、成人1日当たりの摂取量が0.01~100gとなるように用いられることが好ましい。疾患の予防剤又は治療剤及び抗菌剤が、錠剤、トローチ剤、顆粒、ガム、グミ等の固形の形態の場合は、甘露ハチミツが、総質量に対して1~80重量%の範囲で配合されることが好ましい。また、ペースト、液状の場合に、甘露ハチミツの濃度が、総重量に対して0.01~80重量%の範囲で配合されることが好ましい。さらに、本発明の疾患の予防剤又は治療剤及び抗菌剤を経口摂取した直後の人又は動物の唾液中に、甘露ハチミツが2~100mg/mlの範囲で存在するように配合することが、さらに好ましい。 Furthermore, in the disease prophylactic or therapeutic agent and the antibacterial agent of the present invention, honeydew honey is preferably used at an intake of 0.01 to 100 g per adult per day. When the prophylactic or therapeutic agent for disease and the antibacterial agent are solid forms such as tablets, lozenges, granules, gums, gummies, etc., honeydew honey is blended in the range of 1 to 80% by weight based on the total mass. preferably. In addition, in the case of paste or liquid, it is preferable that the concentration of honeydew honey is in the range of 0.01 to 80% by weight based on the total weight. Furthermore, it is further preferable that honeydew honey is present in the saliva of a human or animal immediately after oral intake of the prophylactic or therapeutic agent for diseases and the antibacterial agent of the present invention in the range of 2 to 100 mg/ml. preferable.

本発明の疾患の予防又は治療剤及び抗菌剤には種々の添加物、例えば食品の場合には、各種栄養素、種々のビタミン、ミネラル、フラボノイド類、ポリフェノール類、アミノ酸、食物繊維、多価不飽和脂肪酸、分散剤、及び乳化剤等の安定剤、着色料、香料、甘味料、呈味成分、フレーバー、その他のハチミツ成分、ローヤルゼリー、プロポリス等を配合することができる。 Various additives are added to the agent for preventing or treating diseases and the antibacterial agent of the present invention. Stabilizers such as fatty acids, dispersants and emulsifiers, coloring agents, fragrances, sweeteners, taste components, flavors, other honey components, royal jelly, propolis and the like can be blended.

本発明の疾患の予防剤又は治療剤及び抗菌剤は、安全性が高く、低濃度でジンジバリス菌等の口腔細菌を除去することができることから、ジンジバリス菌等の口腔細菌を原因とする各種疾患を予防又は治療するために用いることができる。ジンジバリス菌等の口腔細菌を原因とする疾患としては、歯周病、虫歯、口臭、認知症、糖尿病、動脈硬化症などが挙げられる。また、これら疾患による合併症についても含まれる。 The prophylactic or therapeutic agent and antibacterial agent for diseases of the present invention are highly safe and can remove oral bacteria such as Lactobacillus gingivalis at a low concentration. It can be used prophylactically or therapeutically. Diseases caused by oral bacteria such as Lactobacillus gingivalis include periodontal disease, tooth decay, halitosis, dementia, diabetes, and arteriosclerosis. It also includes complications due to these diseases.

以下、実施例を通じて本発明をさらに詳細に説明する。ただし、本発明の範囲がこれら実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail through examples. However, the scope of the present invention is not limited to these examples.

Porphyromonas gingivalis (JCM 12257)、及び、Porphyromonas gingivalis (ATCC 49417)をNV加ABHK寒天培地(日水製薬製)に接種し、37℃、嫌気条件下で7日間培養後、生理食塩水を用いて、菌数が108/mLになるように調製したものを試験菌液とした。変法GAM液体培地(日水製薬製)に試験菌液を接種し、37℃、嫌気条件で4日間培養した。4日間の培養後、菌の発育有無を肉眼で観察して、MIC(最少発育阻止濃度)を判定した。 Porphyromonas gingivalis (JCM 12257) and Porphyromonas gingivalis (ATCC 49417) were inoculated on NV-added ABHK agar medium (manufactured by Nissui Pharmaceutical Co., Ltd.), cultured at 37 ° C. under anaerobic conditions for 7 days, and then using physiological saline. A test bacterial solution was prepared so that the bacterial count was 10 8 /mL. A modified GAM liquid medium (manufactured by Nissui Pharmaceutical Co., Ltd.) was inoculated with the test bacterial solution and cultured at 37° C. under anaerobic conditions for 4 days. After culturing for 4 days, the presence or absence of bacterial growth was observed with the naked eye, and the MIC (Minimum Inhibitory Concentration) was determined.

甘露ハチミツであるトルコ産松の木由来パインハニーを20重量%となるように液体培地に混合した。これを試験試料として、液体培地を用いて2倍希釈系列を合計10段階調製した。その結果を表1、表2、表3に示す。JCM 12257に対するMICは、0.26重量%であり、ATCC 49417に対するMICは0.31重量%であった。 Pine honey derived from Turkish pine trees, which is honeydew honey, was mixed with the liquid medium to a concentration of 20% by weight. Using this as a test sample, a total of 10 two-fold dilution series were prepared using a liquid medium. The results are shown in Tables 1, 2 and 3. The MIC for JCM 12257 was 0.26 wt% and the MIC for ATCC 49417 was 0.31 wt%.

甘露ハチミツであるギリシャ産オーク由来オークハニーを20重量%となるように液体培地に混合した。これを試験試料として、液体培地を用いて2倍希釈系列を合計10段階調製した。その結果を表1に示す。JCM 12257に対するMICは、0.62重量%であり、ATCC 49417に対するMICは0.62重量%であった。 Greek oak-derived oak honey, which is honeydew honey, was mixed with the liquid medium to a concentration of 20% by weight. Using this as a test sample, a total of 10 two-fold dilution series were prepared using a liquid medium. Table 1 shows the results. The MIC for JCM 12257 was 0.62 wt% and the MIC for ATCC 49417 was 0.62 wt%.

オーストリア産もみの木由来の甘露ハチミツを20重量%となるように液体培地に混合した。これを試験試料として、液体培地を用いて2倍希釈系列を合計10段階調製した。その結果を表1に示す。JCM 12257に対するMICは、0.31重量%であり、ATCC 49417に対するMICは0.62重量%であった。 Honeydew honey derived from an Austrian fir tree was mixed with the liquid medium to a concentration of 20% by weight. Using this as a test sample, a total of 10 two-fold dilution series were prepared using a liquid medium. Table 1 shows the results. The MIC for JCM 12257 was 0.31 wt% and the MIC for ATCC 49417 was 0.62 wt%.

比較例1Comparative example 1

花ハチミツである国内産アカシアハチミツを20重量%となるように液体培地に混合した。これを試験試料として、液体培地を用いて2倍希釈系列を合計10段階調製した。その結果を表1に示す。JCM 12257に対するMICは、5重量%であり、ATCC 49417に対するMICは5重量%であった。 Domestic acacia honey, which is flower honey, was mixed with the liquid medium to a concentration of 20% by weight. Using this as a test sample, a total of 10 two-fold dilution series were prepared using a liquid medium. Table 1 shows the results. The MIC for JCM 12257 was 5 wt% and the MIC for ATCC 49417 was 5 wt%.

比較例2Comparative example 2

花ハチミツであるニュージーランド産マヌカハニー573+/UMF16+を20重量%となるように液体培地に混合した。これを試験試料として、液体培地を用いて2倍希釈系列を合計10段階調製した。その結果を表1に示す。JCM 12257に対するMICは、2.5重量%であり、ATCC 49417に対するMICは2.5重量%であった。 Manuka honey 573+/UMF16+ produced in New Zealand, which is a flower honey, was mixed with the liquid medium to a concentration of 20% by weight. Using this as a test sample, a total of 10 two-fold dilution series were prepared using a liquid medium. Table 1 shows the results. The MIC for JCM 12257 was 2.5 wt% and the MIC for ATCC 49417 was 2.5 wt%.

Figure 0007198547000001
Figure 0007198547000001

Figure 0007198547000002
Figure 0007198547000002

Figure 0007198547000003
Figure 0007198547000003

Claims (5)

ポルフィロモナス・ジンジバリスが原因で発症する疾病の予防又は治療剤であって、前記疾患が、歯周病及びから選択される1又は複数であり、甘露ハチミツを有効成分とする疾病の予防又は治療剤。 A prophylactic or therapeutic agent for diseases caused by Porphyromonas gingivalis , wherein the disease is one or more selected from periodontal disease and halitosis , and honeydew honey is used as an active ingredient. or therapeutic agents. 前記甘露ハチミツが、松の木由来である請求項に記載の予防又は治療剤。 The preventive or therapeutic agent according to claim 1 , wherein the honeydew honey is derived from pine trees. 甘露ハチミツを有効成分とする、ポルフィロモナス・ジンジバリスに対する抗菌剤。 An antibacterial agent against Porphyromonas gingivalis containing honeydew honey as an active ingredient. 前記甘露ハチミツが、松の木由来である請求項に記載の抗菌剤。 4. The antibacterial agent according to claim 3 , wherein said honeydew honey is derived from pine trees. 甘露ハチミツを有効成分として含み、ポルフィロモナス・ジンジバリスの増殖を抑制するための口腔用組成物であり、前記口腔用組成物が、歯磨き剤、洗口剤、塗布剤、マウススプレー、貼付剤、シート剤、口腔内徐放剤、咀嚼剤、口腔内溶解剤、口腔内崩壊剤、義歯ケア剤、舌ケア剤、口中清涼剤、トローチ剤、含嗽剤、食品組成物、サプリメント、及びドリンク剤から選ばれる口腔用組成物。
An oral composition comprising honeydew honey as an active ingredient and for suppressing the growth of Porphyromonas gingivalis, wherein the oral composition comprises a toothpaste, a mouthwash, a coating agent, a mouth spray, a patch, Sheets, oral sustained release agents, chewing agents, oral dissolving agents, oral disintegrating agents, denture care agents, tongue care agents, mouth fresheners, lozenges, gargles, food compositions, supplements, and drinks A selected oral composition.
JP2022144746A 2022-09-12 2022-09-12 Prophylactic or therapeutic agents, antibacterial agents, and oral compositions Active JP7198547B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022144746A JP7198547B1 (en) 2022-09-12 2022-09-12 Prophylactic or therapeutic agents, antibacterial agents, and oral compositions
PCT/JP2023/031000 WO2024057898A1 (en) 2022-09-12 2023-08-28 Prophylactic or preventive agent, antibacterial agent, and oral composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022144746A JP7198547B1 (en) 2022-09-12 2022-09-12 Prophylactic or therapeutic agents, antibacterial agents, and oral compositions

Publications (2)

Publication Number Publication Date
JP7198547B1 true JP7198547B1 (en) 2023-01-04
JP2024039967A JP2024039967A (en) 2024-03-25

Family

ID=84777473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022144746A Active JP7198547B1 (en) 2022-09-12 2022-09-12 Prophylactic or therapeutic agents, antibacterial agents, and oral compositions

Country Status (2)

Country Link
JP (1) JP7198547B1 (en)
WO (1) WO2024057898A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170072024A1 (en) * 2014-05-14 2017-03-16 Melipharm Antimicrobial composition comprising a carbohydrate, glucose oxidase and zinc oxide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170072024A1 (en) * 2014-05-14 2017-03-16 Melipharm Antimicrobial composition comprising a carbohydrate, glucose oxidase and zinc oxide

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF VETERINARY SCIENCES AND ANIMAL HUSBANDRY, vol. 1(2), JPN6022046168, 2016, pages 7 - 10, ISSN: 0004911253 *
International Journal of Veterinary Sciences and Animal Husbandry,2016年,1(2),pp.7-10
JPN J ORAL BIOL., vol. 36, JPN6022046169, 1994, pages 263 - 273, ISSN: 0004911254 *
Jpn J Oral Biol.,1994年,36,pp.263-273
LEBENSM-WISS U-TECHNOL., vol. 30, JPN6022046166, 1997, pages 748 - 753, ISSN: 0004911252 *
Lebensm-Wiss u-Technol.,1997年,30,pp.748-753
SCIENTIFIC REPORTS, vol. 8, JPN6022046165, 2018, pages 1 - 9, ISSN: 0004911251 *
Scientific Reports,2018年,8,9061, pp.1-9

Also Published As

Publication number Publication date
WO2024057898A1 (en) 2024-03-21
JP2024039967A (en) 2024-03-25

Similar Documents

Publication Publication Date Title
US8183215B2 (en) Method of administering oral flora-improving agent, antibacterial agent and growth promoter
WO2018062605A1 (en) Toothpaste composition containing galenical extract
KR20170141053A (en) Composition for prevention or treatment of dental disease comprising an extract of Gardenia jasminoides
JP7198547B1 (en) Prophylactic or therapeutic agents, antibacterial agents, and oral compositions
KR20170141034A (en) Composition for prevention or treatment of dental disease comprising Panax ginseng extract
US20050152852A1 (en) Use of antibacterial component extracted from cacao mass for inhibiting the growth of periodontal bacteria
KR101671061B1 (en) Composition for the prevention or treatment of periodontal disease comprising extract of Fermented Ponciri Fructus
KR20170141030A (en) Composition for prevention or treatment of dental disease comprising cistanoside A
KR20170141027A (en) Composition for prevention or treatment of dental disease comprising an extract of Astragalus membranaceus
KR20150136656A (en) Compositions for preventing, improving or treating periodontal diseases
RU2618889C1 (en) Mouthwash agent having antiinflammatory, antimicrobial, wound-healing effect
KR102632336B1 (en) Composition for prevention or treatment of dental disease comprising an extract of Daphne genkwa
KR20150120758A (en) Composition for preventing or treating oral disease comprising Glabridin
US20160213604A1 (en) Compositions and methods for reducing caries-causing oral bacteria
JPH05255101A (en) Inhibitor for adhesion of microorganism to animal cell
JP6918529B2 (en) Oral composition
KR20170134123A (en) Composition for prevention or treatment of dental disease comprising astragaloside
KR20240081680A (en) Oral composition containing sericin and poly-gamma-glutamic acid
KR102541843B1 (en) Composition for prevention or treatment of oral disease comprising Arctiin
KR102548925B1 (en) Composition for prevention or treatment of oral disease comprising Scopoletin
JP2009274957A (en) Bactericidal agent against pathogenic bacterium of periodontal disease comprising red longhorn frass as active ingredient
KR20150120756A (en) Composition for preventing or treating oral disease comprising Echinacoside
JP6047105B2 (en) Disinfectant
JP2023102536A (en) oral care agent
KR20190073135A (en) Compositions for preventing or treating periodontal disease comprising extract of maple

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220912

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221212

R150 Certificate of patent or registration of utility model

Ref document number: 7198547

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150